These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32811873)
1. STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. Canesin G; Maggio V; Palominos M; Stiehm A; Contreras HR; Castellón EA; Morote J; Paciucci R; Maitland NJ; Bjartell A; Hellsten R Sci Rep; 2020 Aug; 10(1):13958. PubMed ID: 32811873 [TBL] [Abstract][Full Text] [Related]
2. The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. Canesin G; Evans-Axelsson S; Hellsten R; Sterner O; Krzyzanowska A; Andersson T; Bjartell A Eur Urol; 2016 Mar; 69(3):400-4. PubMed ID: 26144873 [TBL] [Abstract][Full Text] [Related]
3. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. Don-Doncow N; Escobar Z; Johansson M; Kjellström S; Garcia V; Munoz E; Sterner O; Bjartell A; Hellsten R J Biol Chem; 2014 Jun; 289(23):15969-78. PubMed ID: 24755219 [TBL] [Abstract][Full Text] [Related]
4. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB. Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV Mol Cancer Ther; 2016 May; 15(5):806-18. PubMed ID: 26826115 [TBL] [Abstract][Full Text] [Related]
5. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. Hellsten R; Johansson M; Dahlman A; Sterner O; Bjartell A PLoS One; 2011; 6(7):e22118. PubMed ID: 21779382 [TBL] [Abstract][Full Text] [Related]
6. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422 [TBL] [Abstract][Full Text] [Related]
7. The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Hellsten R; Lilljebjörn L; Johansson M; Leandersson K; Bjartell A Prostate; 2019 Oct; 79(14):1611-1621. PubMed ID: 31348843 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365 [TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653 [TBL] [Abstract][Full Text] [Related]
10. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer. Wang L; Lyu C; Stadlbauer B; Buchner A; Nößner E; Pohla H Prostate; 2024 Feb; 84(2):131-147. PubMed ID: 37828768 [TBL] [Abstract][Full Text] [Related]
11. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties. Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201 [TBL] [Abstract][Full Text] [Related]
12. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer. Huang H; Wang C; Liu F; Li HZ; Peng G; Gao X; Dong KQ; Wang HR; Kong DP; Qu M; Dai LH; Wang KJ; Zhou Z; Yang J; Yang ZY; Cheng YQ; Tian QQ; Liu D; Xu CL; Xu DF; Cui XG; Sun YH Clin Cancer Res; 2018 Sep; 24(18):4612-4626. PubMed ID: 29691294 [No Abstract] [Full Text] [Related]
13. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. Handle F; Puhr M; Schaefer G; Lorito N; Hoefer J; Gruber M; Guggenberger F; Santer FR; Marques RB; van Weerden WM; Claessens F; Erb HHH; Culig Z Mol Cancer Ther; 2018 Dec; 17(12):2722-2731. PubMed ID: 30254184 [TBL] [Abstract][Full Text] [Related]
14. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. García V; Lara-Chica M; Cantarero I; Sterner O; Calzado MA; Muñoz E Oncotarget; 2016 Jan; 7(4):4490-506. PubMed ID: 26683224 [TBL] [Abstract][Full Text] [Related]
15. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells. Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346 [TBL] [Abstract][Full Text] [Related]
16. Investigation of ovatodiolide, a macrocyclic diterpenoid, as a potential inhibitor of oral cancer stem-like cells properties via the inhibition of the JAK2/STAT3/JARID1B signal circuit. Lin CS; Bamodu OA; Kuo KT; Huang CM; Liu SC; Wang CH; Tzeng YM; Chao TY; Yeh CT Phytomedicine; 2018 Jul; 46():93-103. PubMed ID: 30097127 [TBL] [Abstract][Full Text] [Related]
17. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. Garrido-Rodríguez M; Ortea I; Calzado MA; Muñoz E; García V J Proteomics; 2019 Feb; 193():217-229. PubMed ID: 30626528 [TBL] [Abstract][Full Text] [Related]
18. Garcinol inhibits cancer stem cell-like phenotype via suppression of the Wnt/β-catenin/STAT3 axis signalling pathway in human non-small cell lung carcinomas. Huang WC; Kuo KT; Adebayo BO; Wang CH; Chen YJ; Jin K; Tsai TH; Yeh CT J Nutr Biochem; 2018 Apr; 54():140-150. PubMed ID: 29414668 [TBL] [Abstract][Full Text] [Related]
19. Esculentoside A suppresses breast cancer stem cell growth through stemness attenuation and apoptosis induction by blocking IL-6/STAT3 signaling pathway. Liu C; Dong L; Sun Z; Wang L; Wang Q; Li H; Zhang J; Wang X Phytother Res; 2018 Nov; 32(11):2299-2311. PubMed ID: 30080291 [TBL] [Abstract][Full Text] [Related]
20. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]